CNR1 may reverse progesterone-resistance of endometrial cancer through the ERK pathway.

[1]  Zhi-jie Liu,et al.  Structural and Functional Insights into Cannabinoid Receptors. , 2020, Trends in pharmacological sciences.

[2]  S. Borstnar,et al.  Cannabinoids and Hormone Receptor-Positive Breast Cancer Treatment , 2020, Cancers.

[3]  J. Liu,et al.  Metformin plus megestrol acetate compared with megestrol acetate alone as fertility‐sparing treatment in patients with atypical endometrial hyperplasia and well‐differentiated endometrial cancer: a randomised controlled trial , 2020, BJOG : an international journal of obstetrics and gynaecology.

[4]  R. Swann,et al.  Presenting symptoms of cancer and stage at diagnosis: evidence from a cross-sectional, population-based study , 2019, The Lancet. Oncology.

[5]  X. Zhuang,et al.  Membrane-associated periodic skeleton is a signaling platform for RTK transactivation in neurons , 2019, Science.

[6]  Zhiming Liu,et al.  DACH1 suppresses epithelial to mesenchymal transition (EMT) through Notch1 pathway and reverses progestin resistance in endometrial carcinoma , 2019, Cancer medicine.

[7]  M. Maccarrone,et al.  Identification of Novel Predictive Biomarkers for Endometrial Malignancies: N-Acylethanolamines , 2019, Front. Oncol..

[8]  G. Giannelli,et al.  Down-Regulation of Cannabinoid Type 1 (CB1) Receptor and its Downstream Signaling Pathways in Metastatic Colorectal Cancer , 2019, Cancers.

[9]  Youheng Wei,et al.  Metformin sensitizes endometrial cancer cells to progestin by targeting TET1 to downregulate glyoxalase I expression. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[10]  M. Jung,et al.  Role of Cannabinoid Receptor Type 1 in Insulin Resistance and Its Biological Implications , 2019, International journal of molecular sciences.

[11]  H. Mackay,et al.  Endocrine therapy in endometrial cancer: An old dog with new tricks. , 2019, Gynecologic oncology.

[12]  H. Kitchener,et al.  The impact of obesity and bariatric surgery on circulating and tissue biomarkers of endometrial cancer risk , 2018, International journal of cancer.

[13]  G. Montgomery,et al.  Progesterone Resistance in Endometriosis: an Acquired Property? , 2018, Trends in Endocrinology & Metabolism.

[14]  P. Rensen,et al.  Regulation of Adipose Tissue Metabolism by the Endocannabinoid System , 2018, Trends in Endocrinology & Metabolism.

[15]  T. Efferth,et al.  Phytochemicals as inhibitors of NF‐&kgr;B for treatment of Alzheimer's disease , 2017, Pharmacological research.

[16]  Xiao-Mei Yang,et al.  Cholesterol Synthetase DHCR24 Induced by Insulin Aggravates Cancer Invasion and Progesterone Resistance in Endometrial Carcinoma , 2017, Scientific Reports.

[17]  E. Darai,et al.  Endometrial cancer , 2016, The Lancet.

[18]  A. Mitsuhashi,et al.  Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  J. Nam,et al.  Progestins in the fertility-sparing treatment and retreatment of patients with primary and recurrent endometrial cancer. , 2015, The oncologist.

[20]  R. Shao.  Progesterone receptor isoforms A and B: new insights into the mechanism of progesterone resistance for the treatment of endometrial carcinoma , 2013, Ecancermedicalscience.

[21]  S. Bulun,et al.  Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer. , 2013, Endocrine reviews.

[22]  J. Deschamps,et al.  Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance. , 2012, Cell metabolism.

[23]  E. Lam,et al.  Mechanisms of endometrial progesterone resistance , 2012, Molecular and Cellular Endocrinology.

[24]  Rochelle L. Garcia,et al.  Biomarkers of progestin therapy resistance and endometrial hyperplasia progression. , 2012, American journal of obstetrics and gynecology.

[25]  Jia-xin Yang,et al.  Fertility-preserving treatment in young women with well-differentiated endometrial carcinoma and severe atypical hyperplasia of endometrium. , 2009, Fertility and sterility.

[26]  P. Stattin,et al.  A high cannabinoid CB(1) receptor immunoreactivity is associated with disease severity and outcome in prostate cancer. , 2009, European journal of cancer.

[27]  Juan F. García,et al.  Sparing fertility in young patients with endometrial cancer. , 2008, Gynecologic oncology.

[28]  H. Tsuda,et al.  Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Patrick Neven,et al.  Endometrial cancer , 2005, The Lancet.

[30]  D. Bodurka,et al.  Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review. , 2004, Gynecologic oncology.